［1］ Stein H, Mason D Y, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells［J］. Blood， 1985，66（4）: 848-858.
[2] Amin H M, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma［J］. Blood， 2007， 110(7): 2259-2267.
[3] Dearden C E,Johnson R, Pettengell R, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)［J］. Br J Haematol， 2011, 153(4):451-85.
[4] Morris S W, Kirstein M N, Valentine M B, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma［J］. Science， 1994,263(5151): 1281-1284.
[5] Shiota M, Fujimoto J, Semba T, et al. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3［J］. Oncogene， 1994, 9(6): 1567-1574.
[6] Swerdlow S H, Campo E, Harris N L, et al. Eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues［J］. Lyon: IARC, 2008:312-316.
[7] Laurent C, Do C, Gascoyne R D, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis［J］. J Clin Oncol， 2009, 27(25):4211-4216.
[8] Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T/null lymphomas (“ALK lymphomas”) with a wide morphological spectrum［J］. Am J Pathol， 1998,153:875-886.
[9] Pearson J D, Lee J K, Bacani J T, et al. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma［J］. Int J Clin Exp Pathol， 2011, 4(2):124-33.
[10] Turner S D, Merz H, Yeung D,et al. CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy［J］. Anticancer Res， 2006,26: 3275-3279.
[11] Amin H M, McDonnell T J, Ma Y, et al. Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma［J］. Oncogene， 2004,23:5426-5434.
[12] Amin H M, Medeiros L J, Ma Y, et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma［J］. Oncogene， 2003,22:5399-5407.
[13] Qiu L, Lai R, Lin Q, et al. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK- anaplastic large-cell lymphoma［J］. Blood， 2006, 108:2407-2415.
[14] Honorat J F, Ragab A, Lamant L ,et al.SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling［J］. Blood， 2006,107:4130-4138.
[15] Han Y, Amin H M, Franko B, et al. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK- anaplastic large-cell lymphoma［J］. Blood， 2006,108:2796-2803.
[16] Gu T L, Tothova Z, Scheijen B, et al. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a［J］. Blood， 2004,103:4622-4629.
[17] Rust R, Harms G, Blokziji T, et al. High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma［J］. J Clin Pathol， 2005,58:520-524.
[18] Schlette E J, Medeiros L J, Goy A, et al. Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma［J］. J Clin Oncol， 2004,22:1682-1688.
[19] Ritter U, Damm-Welk C, Fuchs U, et al.. Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCL) ［J］. Oligonucleotides， 2003,13: 365-373.